Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function

被引:6
|
作者
Hartmann, Thorsten [1 ]
Overhagen, Sabrina [2 ]
Ouwens, D. Margriet [2 ,3 ,4 ]
Raschke, Silja [1 ]
Wohlfart, Paulus [5 ]
Tennagels, Norbert [5 ]
Wronkowitz, Nina [1 ]
Eckel, Juergen [1 ,3 ]
机构
[1] German Diabet Ctr, Paul Langerhans Grp Integrat Physiol, Aufm Hennekamp 65, D-40225 Dusseldorf, Germany
[2] German Diabet Ctr, Inst Clin Biochem & Pathobiochem, D-40225 Dusseldorf, Germany
[3] German Ctr Diabet Res DZD, D-85764 Munich, Germany
[4] Ghent Univ Hosp, Dept Endocrinol, B-9000 Ghent, Belgium
[5] Sanofi Aventis Deutschland GmbH, R&D Diabet Div, D-65929 Frankfurt, Germany
关键词
Insulin glargine; Insulin degludec; Cardiac action; Insulin analogues; MYOCARDIAL ISCHEMIA/REPERFUSION INJURY; ADRENERGIC-RECEPTOR BLOCKADE; BASAL INSULIN; NPH INSULIN; TIME-ACTION; HEART-RATE; RISK; HYPOGLYCEMIA; METAANALYSIS; METABOLISM;
D O I
10.1186/s12933-016-0410-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The effects of insulin on cardiomyocytes, such as positive inotropic action and glucose uptake are well described. However, in vitro studies comparing long-acting insulin analogues with regard to cardiomyocyte signalling and function have not been systematically conducted. Methods: Insulin receptor (IR) binding was assessed using membrane embedded and solubilised IR preparations. Insulin signalling was analysed in adult rat ventricular myocytes (ARVM) and HL-1 cardiac cells. Inotropic effects were examined in ARVM and the contribution of Akt to this effect was assessed by specific inhibition with triciribine. Furthermore, beating-rate in Cor.4U (R) human cardiomyocytes, glucose uptake in HL-1 cells, and prevention from H2O2 induced caspase 3/7 activation in cardiac cells overexpressing the human insulin receptor (H9c2-E2) were analysed. One-way ANOVA was performed to determine significance between conditions. Results: Insulin degludec showed significant lower IR affinity in membrane embedded IR preparations. In HL-1 cardiomyocytes, stimulation with insulin degludec resulted in a lower Akt(Ser(473)) and Akt(Thr(308)) phosphorylation compared to insulin, insulin glargine and its active metabolite M1 after 5- and 10-min incubation. After 60-min treatment, phosphorylation of Akt was comparable for all insulin analogues. Stimulation of glucose uptake in HL-1 cells was increased by 40-60 %, with a similar result for all analogues. Incubation of electrically paced ARVM resulted for all insulins in a significantly increased sarcomere shortening, contractility- and relaxation-velocity. This positive inotropic effect of all insulins was Akt dependent. Additionally, in Cor.4U (R) cardiomyocytes a 10-20 % increased beating-rate was detected for all insulins, with slower onset of action in cells treated with insulin degludec. H9c2-E2 cells challenged with H2O2 showed a fivefold increase in caspase 3/7 activation, which could be abrogated by all insulins used. Conclusions: In conclusion, we compared for the first time the signalling and functional impact of the long-acting insulin analogues insulin glargine and insulin degludec in cardiomyocyte cell models. We demonstrated similar efficacy under steady-state conditions relative to regular insulin in functional endpoint experiments. However, it remains to be shown how these results translate to the in vivo situation.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
    Thorsten Hartmann
    Sabrina Overhagen
    D. Margriet Ouwens
    Silja Raschke
    Paulus Wohlfart
    Norbert Tennagels
    Nina Wronkowitz
    Jürgen Eckel
    Cardiovascular Diabetology, 15
  • [2] Effect of the long-acting insulin analogues glargine and degludec on cardiac cell function
    Hartmann, T.
    Wronkowitz, N.
    Greulich, S.
    Ouwens, M.
    Wohlfart, P.
    Tennagels, N.
    Eckel, J.
    DIABETOLOGIA, 2015, 58 : S261 - S262
  • [3] Characterisation of the cardiac function of human insulin, the long-acting insulin analogues M1-glargine and degludec in adult rat ventricular cardiomyocytes
    Wohlfart, P.
    Hartmann, T.
    Wronkowitz, N.
    Eckel, J.
    Tennagels, N.
    DIABETOLOGIA, 2016, 59 : S241 - S241
  • [4] The effect of long-acting insulin analogues, glargine or detemir, in Type 2 diabetes
    Dissanayake, S.
    Balakrisna-Rao, P.
    Ahmed, A. B.
    DIABETIC MEDICINE, 2007, 24 : 75 - 75
  • [5] More from PHARMAC on long-acting insulin analogues: insulin glargine now funded
    Moodie, Peter
    NEW ZEALAND MEDICAL JOURNAL, 2006, 119 (1236) : 118 - 119
  • [6] Long-acting insulin analogues
    Holt, R
    DIABETES OBESITY & METABOLISM, 2003, 5 (04): : 270 - 270
  • [7] Insulin glargine: A new long-acting insulin product
    Reinhart, L
    Panning, CA
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (07) : 643 - 649
  • [8] Insulin glargine (Lantus), a new long-acting insulin
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2001, 43 (1110): : 65 - 66
  • [9] An update on the long-acting insulin analogue glargine
    Thisted, Henriette
    Johnsen, Soren Paaske
    Rungby, Jorgen
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 99 (01) : 1 - 11
  • [10] Long-acting Insulin Analogues: Focuses better Effect
    不详
    DIABETES STOFFWECHSEL UND HERZ, 2015, 24 (03): : 4 - 7